GW Pharmaceuticals (GWP)

Business description

GW Pharmaceuticals is a UK-based speciality pharma company focused on developing cannabinoid medicines. Lead product, Sativex, is marketed in a number of European countries for multiple sclerosis-associated spasticity.

Share price chart

Share chart

Stock data

Market cap.£970.3m
Last close409.75p
High / Low (52 weeks)523.5p / 219.2p
Stock market listingLN, US
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual14.310.263.6
Relative *11.54.357.4

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Abzena Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Addex Therapeutics
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris Agennix
Alchemia Alexza Pharmaceuticals
Algeta ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Astex Pharmaceuticals Athersys
Avacta Group AVEO Pharmaceuticals
Avita Medical Balda
Basilea Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences Inv BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
BTG Can-Fite BioPharma
Capstone Therapeutics Cardio3 BioSciences
CARMAT Celldex Therapeutics
Cellectis Circadian Technologies
Clavis Pharma Cleveland BioLabs
Clinigen Clinuvel
Consort Medical Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics EKF Diagnostics
Emergent BioSolutions Endocyte
Epigenomics Epistem Holdings
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Futura Medical
Galapagos Galmed Pharmaceuticals
Genfit Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
Halozyme Therapeutics Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunodiagnostic Systems Holdings
ImmuPharma Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Invion Ion Beam Applications
Ipsogen Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Ligand Pharmaceuticals Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
Midatech MolMed
Mologen AG MorphoSys
Nanobiotix Nanosonics
Nektar Therapeutics Neovacs
Newron Pharmaceuticals NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novogen NPS Pharmaceuticals
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Prescient Therapeutics
Prima BioMed ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Quantum Pharmaceuticals
Regeneus ReNeuron Group
Resverlogix REVA Medical
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
Tekmira TESARO
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Topotarget
Transgene Trillium Therapeutics
Trimel Pharmaceuticals UCB
UDG Healthcare uniQure NV
Vectura Verastem
Verisante Technology Vernalis
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus WaferGen Biosystems
Wilex Xencor
Zafgen Zealand Pharma
Zeltia Ziopharm Oncology

Company news

Today's Winner And Loser: GW Pharmaceuticals plc Pushes Higher As Circle ...

Fri, 09 Jan 2015 10:30:00 GMT

PEG Ratio (5 yr expected):

Tue, 25 Mar 2014 09:01:13 GMT

BUZZ-GW Pharmaceuticals Plc: Cannabis drug fails cancer pain

Thu, 08 Jan 2015 14:15:00 GMT

GW Pharmaceuticals plc Reports 2014 Q4 and Full Year Financial Results

Tue, 02 Dec 2014 12:04:51 GMT

GW Pharmaceuticals PLC: A Pre-Earnings Preview

Tue, 18 Nov 2014 00:33:45 GMT

Y/E Sep Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2013A 27.3 (8.9) (9.7) (2.6) N/A N/A
2014A 30.0 (17.0) (18.3) (6.4) N/A N/A
2015E N/A N/A N/A N/A N/A N/A
2016E N/A N/A N/A N/A N/A N/A

Last updated on 18/12/2014

Investment summary

NASDAQ follow-on offerings totalling $212m (£126.3m) enable increased R&D spend for pipeline progress. Four GW-run Epidiolex refractory childhood epilepsy clinical trials should be underway in 2015 (the first, a Phase II/III Dravet Syndrome trial, is recruiting). October's R&D day updated interim data from ongoing physician-led open-label Epidiolex studies. In 58-pts with at least 12 weeks' continuous Epidiolex exposure, median reduction in total seizure frequency (all seizure types/syndromes) was 36% over the 12-week period, with 40% showing a 50% or greater reduction. For the 12-pts with Dravet Syndrome (initial target indication for commercialisation) median overall reduction in convulsive seizure frequency was 51-72% across a range of time points and analyses. GW's next inflection point is Phase III Sativex cancer pain data; top-line data from two trials are expected in early-2015 and Q215 respectively. Positive read out would lead to GW’s first FDA filing in H215.

Last updated on 22/12/2014

Industry outlook

GW is the leading player in cannabinoid medicines, which have the potential to become novel therapies for a broad range of diseases. Cannabinoids are diverse chemical compounds that GW extracts from different cannabis plant varieties (chemotypes) it has bred.

Last updated on 22/12/2014

Key management

Geoffrey Guy, Chairman
Justin Gover, CEO
Adam David George, CFO

Company address

6th Floor
1 Cavendish Place
London
W1G 0QF
United Kingdom
+44 (0) 1980 557 000
View website